These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 30072404)

  • 1. Sex and BMI Alter the Benefits and Risks of Sulfonylureas and Thiazolidinediones in Type 2 Diabetes: A Framework for Evaluating Stratification Using Routine Clinical and Individual Trial Data.
    Dennis JM; Henley WE; Weedon MN; Lonergan M; Rodgers LR; Jones AG; Hamilton WT; Sattar N; Janmohamed S; Holman RR; Pearson ER; Shields BM; Hattersley AT;
    Diabetes Care; 2018 Sep; 41(9):1844-1853. PubMed ID: 30072404
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preventing Unnecessary Costs of Drug-Induced Hypoglycemia in Older Adults with Type 2 Diabetes in the United States and Canada.
    Boulin M; Diaby V; Tannenbaum C
    PLoS One; 2016; 11(9):e0162951. PubMed ID: 27648831
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness analysis of thiazolidinediones in uncontrolled type 2 diabetic patients receiving sulfonylureas and metformin in Thailand.
    Chirakup S; Chaiyakunapruk N; Chaikledkeaw U; Pongcharoensuk P; Ongphiphadhanakul B; Roze S; Valentine WJ; Palmer AJ
    Value Health; 2008 Mar; 11 Suppl 1():S43-51. PubMed ID: 18387067
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of Hemoglobin A1c Levels With Use of Sulfonylureas, Dipeptidyl Peptidase 4 Inhibitors, and Thiazolidinediones in Patients With Type 2 Diabetes Treated With Metformin: Analysis From the Observational Health Data Sciences and Informatics Initiative.
    Vashisht R; Jung K; Schuler A; Banda JM; Park RW; Jin S; Li L; Dudley JT; Johnson KW; Shervey MM; Xu H; Wu Y; Natrajan K; Hripcsak G; Jin P; Van Zandt M; Reckard A; Reich CG; Weaver J; Schuemie MJ; Ryan PB; Callahan A; Shah NH
    JAMA Netw Open; 2018 Aug; 1(4):e181755. PubMed ID: 30646124
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative cost-effectiveness of metformin-based dual therapies associated with risk of cardiovascular diseases among Chinese patients with type 2 diabetes: Evidence from a population-based national cohort in Taiwan.
    Ou HT; Chen YT; Liu YM; Wu JS
    Diabetes Res Clin Pract; 2016 Jun; 116():14-25. PubMed ID: 27321311
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reducing the Burden of Diabetes Treatment: A Review of Low-cost Oral Hypoglycemic Medications.
    Vaughan EM; Rueda JJ; Samson SL; Hyman DJ
    Curr Diabetes Rev; 2020; 16(8):851-858. PubMed ID: 32026779
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk of Anemia With Metformin Use in Type 2 Diabetes: A MASTERMIND Study.
    Donnelly LA; Dennis JM; Coleman RL; Sattar N; Hattersley AT; Holman RR; Pearson ER
    Diabetes Care; 2020 Oct; 43(10):2493-2499. PubMed ID: 32801130
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prior event rate ratio adjustment produced estimates consistent with randomized trial: a diabetes case study.
    Rodgers LR; Dennis JM; Shields BM; Mounce L; Fisher I; Hattersley AT; Henley WE;
    J Clin Epidemiol; 2020 Jun; 122():78-86. PubMed ID: 32194148
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Race, ethnicity, and use of thiazolidinediones among US adults with diabetes.
    Aquilante CL; Zhang W; McCollum M
    Curr Med Res Opin; 2007 Mar; 23(3):489-94. PubMed ID: 17355730
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Patterns of medication initiation in newly diagnosed diabetes mellitus: quality and cost implications.
    Desai NR; Shrank WH; Fischer MA; Avorn J; Liberman JN; Schneeweiss S; Pakes J; Brennan TA; Choudhry NK
    Am J Med; 2012 Mar; 125(3):302.e1-7. PubMed ID: 22340932
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Economic assessment of troglitazone as an adjunct to sulfonylurea therapy in the treatment of type 2 diabetes.
    Caro JJ; Klittich WS; Raggio G; Kavanagh PL; O'Brien JA; Shomphe LA; Flegel KM; Copley-Merriman C; Sigler C
    Clin Ther; 2000 Jan; 22(1):116-27. PubMed ID: 10688395
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of thiazolidinediones and sulfonylureas in patients with diabetes.
    Derosa G; Maffioli P
    Diabetes Technol Ther; 2010 Jun; 12(6):491-501. PubMed ID: 20470234
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevalence of hypoglycemia among a sample of sulfonylurea-treated patients with Type 2 diabetes mellitus in Argentina: The real-life effectiveness and care patterns of diabetes management (RECAP-DM) study.
    Gonzalez C; Monti C; Pinzon A; Monsanto H; Ejzykowicz F;
    Endocrinol Diabetes Nutr (Engl Ed); 2018 Dec; 65(10):592-602. PubMed ID: 30076124
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness of rosiglitazone combination therapy for the treatment of type 2 diabetes mellitus in the UK.
    Beale S; Bagust A; Shearer AT; Martin A; Hulme L
    Pharmacoeconomics; 2006; 24 Suppl 1():21-34. PubMed ID: 16800160
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adherence to Oral Glucose-Lowering Therapies and Associations With 1-Year HbA1c: A Retrospective Cohort Analysis in a Large Primary Care Database.
    Farmer AJ; Rodgers LR; Lonergan M; Shields B; Weedon MN; Donnelly L; Holman RR; Pearson ER; Hattersley AT
    Diabetes Care; 2016 Feb; 39(2):258-263. PubMed ID: 26681714
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Disease progression and treatment response in data-driven subgroups of type 2 diabetes compared with models based on simple clinical features: an analysis using clinical trial data.
    Dennis JM; Shields BM; Henley WE; Jones AG; Hattersley AT
    Lancet Diabetes Endocrinol; 2019 Jun; 7(6):442-451. PubMed ID: 31047901
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oral antidiabetic agents: current role in type 2 diabetes mellitus.
    Krentz AJ; Bailey CJ
    Drugs; 2005; 65(3):385-411. PubMed ID: 15669880
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects on the incidence of cardiovascular events of the addition of pioglitazone versus sulfonylureas in patients with type 2 diabetes inadequately controlled with metformin (TOSCA.IT): a randomised, multicentre trial.
    Vaccaro O; Masulli M; Nicolucci A; Bonora E; Del Prato S; Maggioni AP; Rivellese AA; Squatrito S; Giorda CB; Sesti G; Mocarelli P; Lucisano G; Sacco M; Signorini S; Cappellini F; Perriello G; Babini AC; Lapolla A; Gregori G; Giordano C; Corsi L; Buzzetti R; Clemente G; Di Cianni G; Iannarelli R; Cordera R; La Macchia O; Zamboni C; Scaranna C; Boemi M; Iovine C; Lauro D; Leotta S; Dall'Aglio E; Cannarsa E; Tonutti L; Pugliese G; Bossi AC; Anichini R; Dotta F; Di Benedetto A; Citro G; Antenucci D; Ricci L; Giorgino F; Santini C; Gnasso A; De Cosmo S; Zavaroni D; Vedovato M; Consoli A; Calabrese M; di Bartolo P; Fornengo P; Riccardi G; ;
    Lancet Diabetes Endocrinol; 2017 Nov; 5(11):887-897. PubMed ID: 28917544
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The cost-effectiveness of dapagliflozin versus sulfonylurea as an add-on to metformin in the treatment of Type 2 diabetes mellitus.
    Charokopou M; McEwan P; Lister S; Callan L; Bergenheim K; Tolley K; Postema R; Townsend R; Roudaut M
    Diabet Med; 2015 Jul; 32(7):890-8. PubMed ID: 25817050
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Important differences in the durability of glycaemic response among second-line treatment options when added to metformin in type 2 diabetes: a retrospective cohort study.
    Mamza J; Mehta R; Donnelly R; Idris I
    Ann Med; 2016; 48(4):224-34. PubMed ID: 26982210
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.